SCHEMBL249069

SCHEMBL249069

C=CCc1c(Cl)cccc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 2/20 0.44
AKR1B1 P15121 1/20 0.41
ALDH1A1 P00352 4/20 0.41
HPGD P15428 2/20 0.41
TDP1 Q9NUW8 2/20 0.40
MAPT P10636 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
GABRA1 P14867 1/20 0.39
GABRB2 P47870 1/20 0.39
CYP1A2 P05177 2/20 0.38
CYP2A6 P11509 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
ADRA2A P08913 1/20 0.37
ADRA2B P18089 1/20 0.37
ADRA2C P18825 1/20 0.37
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7696948 0.85 ALDH1A1 (0.54) TAAR1AKR1B1ALDH1A1HPGDTDP1
SCHEMBL8042811 0.85 TAAR1 (0.55) TAAR1HPGDTDP1MAPTSMN1; SMN2
SCHEMBL5274928 0.85 TSHR (0.45) TAAR1AKR1B1ALDH1A1HPGDTDP1
SCHEMBL15106903 0.80 CYP2A6 (0.50) TAAR1AKR1B1ALDH1A1SMN1; SMN2GABRA1
SCHEMBL10930849 0.80 HPGD (0.46) AKR1B1ALDH1A1HPGDTDP1MAPT
SCHEMBL5830293 0.79 TSHR (0.52) AKR1B1ALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL10365089 0.79 GABRA1 (0.41) TAAR1AKR1B1ALDH1A1HPGDTDP1
SCHEMBL9792845 0.78 CYP3A4 (0.32) ALDH1A1HPGDTDP1MAPTSMN1; SMN2
SCHEMBL11500020 0.78 DPP4 (0.63) ALDH1A1TDP1MAPTKMT2ALMNA
SCHEMBL10325016 0.76 TAAR1 (0.52) TAAR1AKR1B1ALDH1A1HPGDTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0253396-B1 PROCESS FOR PREPARING 5,6-SUBSTITUTED-2,4-QUINAZOLINEDIAMINES AND INTERMEDIATES WARNER-LAMBERT COMPANY (US) 1993-03-17 EP claimed
EP-0253396-A2 Process for preparing 5,6-substituted-2,4-quinazolinediamines and intermediates WARNER-LAMBERT COMPANY (US) 1988-01-20 EP claimed
CN-109939092-B Phenyl carbamate compounds for use in preventing or treating pediatric epilepsy and epilepsy-related syndrome 比皮艾思药物研发有限公司 2022-03-22 CN disclosed
CN-105188690-B Phenyl carbamate compounds for use in preventing or treating movement disorders 比皮艾思药物研发有限公司 2020-06-12 CN disclosed
CN-105188689-B Phenyl carbamate compounds for use in preventing or treating epilepsy and epilepsy-related syndromes 比皮艾思药物研发有限公司 2020-04-10 CN disclosed
CN-110478343-A Phenyl carbamate compound and comprising the compound for preventing or treating the composition of disease caused by nerve gas BIO PHARM SOLUTIONS CO LTD 2019-11-22 CN disclosed
CN-105189450-B Phenyl carbamate compound and composition for preventing or treating mental disorder comprising the same 比皮艾思药物研发有限公司 2019-09-13 CN disclosed
CN-105209430-B Phenyl carbamate compounds and neuroprotective compositions comprising the same 比皮艾思药物研发有限公司 2019-09-13 CN disclosed
CN-109939092-A For preventing or treating the carbanilate compound of children epilepsy and epilepsy related syndromes 比皮艾思药物研发有限公司 2019-06-28 CN disclosed
CN-105388281-B Detect enzyme linked immunological kit and its application of iprodione 中国烟草总公司郑州烟草研究院 2017-09-12 CN disclosed
CN-105388286-B A kind of test strips for detecting iprodione and its preparation method and application 中国烟草总公司郑州烟草研究院 2017-07-07 CN disclosed
WO-2012002773-A2 PHENYLCARBAMATE COMPOUND AND MUSCLE RELAXANT CONTAINING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2012-01-05 WO disclosed
EP-1246815-B1 PHENYLPIPERAZINYL DERIVATIVES LUNDBECK & CO AS H (DK) 2004-03-17 EP disclosed
US-20030083336-A1 Phenylpiperazinyl derivatives H. LUNDBECK A/S (DK) 2003-05-01 US disclosed
EP-1246815-A1 PHENYLPIPERAZINYL DERIVATIVES H. Lundbeck A/S (DK) 2002-10-09 EP disclosed
WO-2001049677-A1 PHENYLPIPERAZINYL DERIVATIVES H. LUNDBECK A/S (DK) 2001-07-12 WO disclosed
EP-0253396-B1 PROCESS FOR PREPARING 5,6-SUBSTITUTED-2,4-QUINAZOLINEDIAMINES AND INTERMEDIATES WARNER-LAMBERT COMPANY (US) 1993-03-17 EP disclosed
EP-0253396-A2 Process for preparing 5,6-substituted-2,4-quinazolinediamines and intermediates WARNER-LAMBERT COMPANY (US) 1988-01-20 EP disclosed
US-4677219-A Substituted benzonitriles WARNER-LAMBERT COMPANY (US) 1987-06-30 US disclosed
US-4560814-A Process for alkylating halogenated and trifluoromethylated benzene compounds RHONE-POULENC SPECIALITES CHIMIQUES (FR) 1985-12-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030083336-A1 Phenylpiperazinyl derivatives DRD4, DRD2, DRD3 TAAR1 101/4885AKR1B1 1515/4885ALDH1A1 840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.